CINJ received a P20 Cancer Center Support Grant (CCSG) planning grant in 1992. These dollars helped recruit a director and established the earliest infrastructure for an NCI-designated cancer center. In 1997, CINJ was awarded a P30 CCSG 1 that included $100,000 annually for developmental funds. It became apparent to the Director that this award could be used as a means to attract matching philanthropic dollars, and each year this amount of money has grown substantially. In 2000, CINJ successfully competed for a five-year CCSG renewal with an """"""""Excellent"""""""" priority score of 171. Developmental Funds received a rating of """"""""Outstanding"""""""" and $280,000 per year was awarded as requested. Based on advice and detailed review by the Internal and External Advisory Boards, plans were developed to enhance clinical and population sciences and interdisciplinary interactions. Developmental Funds played an important role in implementation of this plan by allowing the development of critical shared resources and the recruitment of outstanding new faculty that culminated in designation of CINJ as a Comprehensive Cancer Center in June, 2002. Developmental Funds are used to foster outstanding cancer research. During the last grant period, Developmental Funds provided essential support for outstanding new investigators, supported interdisciplinary pilot studies that led to translationally-focused collaborations, and helped establish new shared resources (e.g., Transcriptional Profiling, Transgenic and Knockout Mouse). In particular, Developmental Funds helped to strengthen the Division of Prevention, Control and Population Science and improved interactions between this division and the Divisions of Basic and Clinical Sciences. During the next grant period, CINJ shall use Developmental Funds to continue to enhance each of the three main scientific divisions of the center, Clinical Science (Prostate; Breast Cancer Research; Cancer Pharmacology/Developmental Therapeutics), Basic Science (Transcriptional Regulation and Oncogenesis; Cytokines, Cytokine Signaling and Cancer; and Molecular Mechanisms of Tumor Growth), and Prevention, Control and Population Science (Carcinogenesis and Chemoprevention; Population Science). To accomplish this aim, Developmental Funds will be used to help recruit new investigators, develop new shared resources, and fund additional pilot projects aimed at fostering inter-disciplinary collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA072720-12
Application #
7731616
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-03-01
Budget End
2009-02-28
Support Year
12
Fiscal Year
2008
Total Cost
$362,344
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Type
DUNS #
617022384
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Chan, Chang S; Laddha, Saurabh V; Lewis, Peter W et al. (2018) ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun 9:4158
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Warner, Wayne A; Lee, Tammy Y; Fang, Fang et al. (2018) The burden of prostate cancer in Trinidad and Tobago: one of the highest mortality rates in the world. Cancer Causes Control 29:685-697
Zhao, Yuhan; Wu, Lihua; Yue, Xuetian et al. (2018) A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models. Elife 7:
Deek, Matthew P; Kim, Sinae; Ahmed, Inaya et al. (2018) Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer. Am J Clin Oncol 41:362-366
O'Malley, Denalee; Dewan, Asa A; Ohman-Strickland, Pamela A et al. (2018) Determinants of patient activation in a community sample of breast and prostate cancer survivors. Psychooncology 27:132-140
Park, Kihan; Chen, Wenjin; Chekmareva, Marina A et al. (2018) Electromechanical Coupling Factor of Breast Tissue as a Biomarker for Breast Cancer. IEEE Trans Biomed Eng 65:96-103
Gupta, Apar; Ohri, Nisha; Haffty, Bruce G (2018) Hypofractionated radiation treatment in the management of breast cancer. Expert Rev Anticancer Ther 18:793-803
Jang, Thomas L; Patel, Neal; Faiena, Izak et al. (2018) Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 124:4010-4022
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212

Showing the most recent 10 out of 775 publications